Figure 3.

Clinical Benefit in patients with RBC transfusion‐dependent lower‐risk myelodysplastic syndromes. This composite endpoint comprises RBC transfusion independence, hematologic improvement in the erythroid lineage, and complete or partial remission, per the International Working Group 2006 criteria for myelodysplastic syndromes [27]. (A): All patients. (B): The subgroup of patients refractory to erythropoiesis‐stimulating agents. (C): The subgroup of patients with isolated anemia.

Abbreviations: CI, confidence interval; ESA, erythropoiesis‐stimulating agent; RBC‐TD, red blood cell transfusion‐dependence.